First author, year of publication, place | Year of data collection | Study design, Sample size | Cancer type | Groups being compared | RR (95%Cl), p-value | Variables adjusted for |
---|---|---|---|---|---|---|
Gupta D, 2009, USA [77] | January 2001 to May 2006 | Retrospective, consecutive case series, 213 | Ovarian | >=3.5 g/dL <3.5 g/dL Used as continuous as well | Univariate: median survival in months (95%CI) Low: 7.3 (4.8 to 9.8) Normal: 23.3 (16.5 to 30.1); p < 0.0001 Multivariate: 0.39 (0.29-0.53), <0.001 | Age, BMI, CA125, tumor stage, treatment history |
Sharma R, 2008, UK [78] | October 2003 to June 2006 | Retrospective, 154 | Ovarian | <3.5 g/dL >=3.5 g/dL | Univariate: 1.71 (0.92-3.18), 0.091 GPS score was prognostic on multivariate analysis | Tumor type, stage, grade, ascites, debulking surgery, ALP, residual disease, CRP |
Alphs HH, 2006, USA [79] | January 1, 1990 to June 30, 2004 | Retrospective, 78 | Ovarian and primary peritoneal | >=3.7 g/dL <3.7 g/dL | Univariate: 0.58 (0.42-0.79), p < 0.00 Multivariate: 0.60 (0.41-0.89), p = 0.01 | Age, race, BMI, Co-morbidity index, surgeon, ASA score, tumor size, intraoperative blood loss, ascites |
Lis CG, 2003, USA [46] | March 1993 to December 1999 | Retrospective consecutive case series, 180 | Breast | >=3.5 g/dL <3.5 g/dL | Multivariate: 3.53, 0.0033 | Abnormal breast antigen, tumor stage, abnormal HER2/Neu readings |
Wyld L 2003, UK [80] | January 1997 to January 2002 | Retrospective, 145 | Breast cancer with liver metastases | First group <3.0 g/dL >=3.0 g/dL Second group <3.5 g/dL >=3.5 g/dL | Median survival in months (95%CI) For first group >=3.0 g/dL = 5.86 (0.16 - 51) <3.0 g/dL = 1.5 (0.16 - 5.13), p = 0.01 For Second group >=3.5 g/dL = 7.0 (0.27 - 51) <3.5 g/dL = 2.0 (0.16 - 27.2) p = 0.01 | LFTs, CEA, bilirubin, age, histological grade, ER status, metastasis, treatment response |
Clark TG, 2001, UK [81] | 01/01/1984 to 31/12/1999 | Retrospective, 1189 | Ovarian | Continuous variable | Univariate: p <= 0.05 Multivariate: 0.97 (0.96, 0.99), 0.036 | Age, FIGO stage, the presence or absence of ascites, performance status, histology, debulking, grade, CA125 and ALP |